OXIS INTERNATIONAL |
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| 06-27 | GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650 | MT |
| 06-27 | GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study | DJ |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 10.56M 9.66M 14.44M |
|---|---|---|---|---|---|
| Net income 2022 | -20M -18.29M -27.34M | Net income 2023 | -7M -6.4M -9.57M | EV / Sales 2022 | - |
| Net cash position 2022 | 16.33M 14.94M 22.33M | Net cash position 2023 | 13.91M 12.72M 19.02M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.35
x | P/E ratio 2023 |
-1.36
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.34% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 61 | 21-01-12 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 22-12-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 23-04-30 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 20-11-10 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 21-01-12 |
GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system.
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Sector
Pharmaceuticals
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +56.75% | 848B | |
| +33.10% | 627B | |
| -0.10% | 363B | |
| +16.06% | 318B | |
| +12.86% | 299B | |
| +15.32% | 243B | |
| +17.23% | 225B | |
| +16.35% | 179B | |
| +5.17% | 167B |
